Prostate cancer early detection, version 2.2015 Journal Article
| Authors: | Carroll, P. R.; Parsons, J. K.; Andriole, G.; Bahnson, R. R.; Barocas, D. A.; Castle, E. P.; Catalona, W. J.; Dahl, D. M.; Davis, J. W.; Epstein, J. I.; Etzioni, R. B.; Farrington, T.; Hemstreet, G. P. 3rd; Kawachi, M. H.; Lange, P. H.; Loughlin, K. R.; Lowrance, W.; Maroni, P.; Mohler, J.; Morgan, T. M.; Nadler, R. B.; Poch, M.; Scales, C.; Shaneyfelt, T. M.; Smaldone, M. C.; Sonn, G.; Sprenke, P.; Vickers, A. J.; Wake, R.; Shead, D. A.; Freedman-Cass, D. |
| Article Title: | Prostate cancer early detection, version 2.2015 |
| Abstract: | Prostate cancer represents a spectrum of disease that ranges from nonaggressive, slow-growing disease that may not require treatment to aggressive, fast-growing disease that does. The NCCN Guidelines for Prostate Cancer Early Detection provide a set of sequential recommendations detailing a screening and evaluation strategy for maximizing the detection of prostate cancer that is potentially curable and that, if left undetected, represents a risk to the patient. The guidelines were developed for healthy men who have elected to participate in the early detection of prostate cancer, and they focus on minimizing unnecessary procedures and limiting the detection of indolent disease. © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. |
| Keywords: | cancer survival; cancer surgery; unclassified drug; gene mutation; overall survival; cancer risk; cancer diagnosis; cancer incidence; treatment indication; prostate specific antigen; gene overexpression; cancer screening; practice guideline; tumor biopsy; brca1 protein; brca2 protein; tumor antigen; tumor marker; hematuria; cancer mortality; age; risk assessment; fever; prostate cancer; early diagnosis; epigenetics; prostatectomy; family history; prostate biopsy; urinary tract infection; comorbidity; sepsis; clinical decision making; prostatic intraepithelial neoplasia; epididymitis; orchitis; physical examination; high risk population; false positive result; life expectancy; transrectal ultrasonography; proteinase inhibitor; disease specific survival; african american; predictive value; european american; cause specific survival; dysuria; hereditary nonpolyposis colorectal cancer; digital rectal examination; rectum hemorrhage; steroid 5alpha reductase inhibitor; infectious complication; prostatitis; unnecessary procedure; patient preference; medical history; local anesthesia; prostate cancer antigen 3; prostate volume; alpha 1 antichymotrypsin; prostate specific antigen velocity; oncological parameters; escherichia coli infection; faintness; image guided biopsy; multiparametric magnetic resonance imaging; human; male; article; first degree relative; hemospermia; male genital tract parameters; confirmmdx; prostate specific antigen density |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 13 |
| Issue: | 12 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2015-12-01 |
| Start Page: | 1534 |
| End Page: | 1561 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 26656522 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 3 February 2016 -- Source: Scopus |
